Questcor (QCOR) Sees Q4, FY11 Revs Above Views
Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it expects to report net sales of approximately $75 million and operating income of approximately $41 million to $43 million for the quarter ended December 31, 2011, as compared to $29.3 million in net sales and $10.8 million in operating income for the quarter ended December 31, 2010. The Company's cash, cash equivalents and short-term investments as of January 31, 2012 was approximately $214 million.
The Street sees revs of $68.2 million.
For the full year ended December 31, 2011, Questcor expects to report net sales of approximately $218 million and operating income of approximately $111 million to $113 million, as compared to $115.1 million in net sales and $53.8 million in operating income for the year ended December 31, 2010.
The Street sees revs of $210.8 million.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
The Street sees revs of $68.2 million.
For the full year ended December 31, 2011, Questcor expects to report net sales of approximately $218 million and operating income of approximately $111 million to $113 million, as compared to $115.1 million in net sales and $53.8 million in operating income for the year ended December 31, 2010.
The Street sees revs of $210.8 million.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Monro Muffler (MNRO) Tops Q4 EPS by 1c; Comps About Flat; Guides FY13 EPS Below Views
- Teva Pharma (TEVA) Sees Weaker FY12 Sales, EPS
- Genesco, Inc. (GCO) Reports Q1 Beat; Boosts FY13 Outlook
Create E-mail Alert Related Categories
Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
